{"id":"W4411690549","doi":"10.1016/j.kint.2025.05.028","title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","year":2025,"lang":"en","type":"article","venue":"Kidney International","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"MorphoSys; BioCryst; Biogen; Novartis","keywords":"Medicine; Placebo; Adverse effect; Renal function; Proteinuria; Urology; Clinical endpoint; Nephropathy; Randomized controlled trial; Creatinine; Internal medicine; Surgery; Gastroenterology; Kidney; Endocrinology; Pathology; Diabetes mellitus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003995379,0.002124801,0.004388039,0.0005720352,0.0008792953,0.001262632,0.001269481,0.002737065,0.01175938],"category_scores_gemma":[0.002864591,0.001164593,0.001585268,0.000582607,0.001680131,0.001235537,0.0004097752,0.003201844,0.001814704],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008164454,"about_ca_system_score_gemma":0.002176638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000680532,"about_ca_topic_score_gemma":0.001715721,"domain_scores_codex":[0.9985132,0.0008276562,0.0001047769,0.0002528411,0.0001302967,0.0001713001],"domain_scores_gemma":[0.9982964,0.000447332,0.0003876289,0.0001768162,0.0001888927,0.0005030176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9785954,0.01056371,0.0003632166,0.0004381859,0.0006391505,0.00002728679,0.00003418731,0.0001158879,0.002494135,0.00006833064,0.000638388,0.006022061],"study_design_scores_gemma":[0.973177,0.02568986,0.0004475226,0.00001082548,0.0001155145,0.00001080014,0.00000419834,0.0000933514,0.0001294655,0.00003334021,0.0002831705,0.000004863058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9392905,0.007619727,0.003124344,0.001666314,0.001874522,0.03827427,0.003462373,0.0004550472,0.004232903],"genre_scores_gemma":[0.9421365,0.003614236,0.005347993,0.003245385,0.001128202,0.03675701,0.002314629,0.00006162197,0.005394469],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01175938,"threshold_uncertainty_score":0.03933901,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02391779420995822,"score_gpt":0.3731227697168931,"score_spread":0.3492049755069349,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}